TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical …
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical …
MS Hofman, L Emmett, J Violet, AY Zhang… - BJU …, 2019 - researchers.mq.edu.au
Objective: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical …
MS Hofman, L Emmett, J Violet, AY Zhang… - BJU …, 2019 - research.monash.edu
Objective: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical …
MS Hofman, L Emmett, J Violet, AY Zhang… - BJU …, 2019 - pubmed.ncbi.nlm.nih.gov
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial …
MS Hofman, L Emmett, J Violet, AY Zhang… - BJU International, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> To assess the activity and safety of
cabazitaxel chemotherapy vs that of treatment with< jats: sup> 177</jats: sup> Lu‐< jats …
cabazitaxel chemotherapy vs that of treatment with< jats: sup> 177</jats: sup> Lu‐< jats …
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical …
MS Hofman, L Emmett, J Violet, NJ Lawrence… - BJU …, 2019 - europepmc.org
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to …
TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical …
MS Hofman, L Emmett, J Violet, AY Zhang… - BJU …, 2019 - search.ebscohost.com
Objective: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …